This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Vanderbilt University Medical Center
ClinicalTrials.gov Identifier:
NCT00533884
First received: September 20, 2007
Last updated: April 5, 2017
Last verified: April 2017
September 20, 2007
April 5, 2017
October 2007
May 2010   (Final data collection date for primary outcome measure)
  • Domain-Specific Neurocognitive Functioning measuring attention, executive functioning, mental processing speed, verbal memory, language, and visuospatial construction at baseline and 3 months after completion of treatment [ Time Frame: Baseline and 3 months post-treatment ]
  • Global neurocognitive functioning as measured by the Mini-Mental State Examination (MMSE) [ Time Frame: Baseline, at each scheduled treatment visit, and at 3 months post-treatment ]
  • Self-reported neurocognitive symptoms as measured by the Alertness Behavior Subscale of the Sickness Impact Profile [ Time Frame: Baseline, at each scheduled treatment visit, and at 3 months post-treatment ]
  • Delirium and delirium symptoms by the NEECHAM Confusion Scale and Confusion Assessment Method (CAM) [ Time Frame: Baseline, at each scheduled treatment visit, and at 3 months post-treatment ]
Not Provided
Complete list of historical versions of study NCT00533884 on ClinicalTrials.gov Archive Site
  • Alcohol, tobacco, and drug use as measured by the Alcohol Use Disorders Identification Test (AUDIT) [ Time Frame: Baseline ]
  • Premorbid intellectual functioning as measured by the North American Adult Reading Test (NAART) [ Time Frame: Baseline ]
  • Functional status measured by the Duke Older Americans Resources and Services (OARS) Activities of Daily Living Scale [ Time Frame: Baseline, at each scheduled treatment visit, and at 3 months post-treatment ]
  • Symptom prevalence and distress measured using the short form of the Memorial Symptom Assessment Scale (MSASSF) [ Time Frame: Baseline, at each scheduled treatment visit, and at 3 months post-treatment ]
  • Mood State measured by the Profile of Mood States (POMS-SF) [ Time Frame: Baseline, at each scheduled treatment visit, and at 3 months post-treatment ]
  • Overall quality of life measured using Cantril's Ladder [ Time Frame: Baseline and 3 months post-treatment ]
  • Coping measured by the Mini-Mental Adjustment to Cancer Scale (Mini-MAC) [ Time Frame: Baseline and 3 months post-treatment ]
  • Hospitalizations, emergency department visits, and unscheduled clinic visits [ Time Frame: At each scheduled treatment visit and 3 months post-treatment ]
  • Falls, injuries, and other complications [ Time Frame: At each scheduled treatment visit and 3 months post-treatment ]
Not Provided
Not Provided
Not Provided
 
Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic
Neurocognitive Functioning in Adults With Upper Aerodigestive System Cancers

RATIONALE: Gathering information about how often problems with neurocognitive functioning occur in patients with newly diagnosed upper aerodigestive tract cancers may help doctors learn more about the disease.

PURPOSE: This clinical trial is studying neurocognitive functioning in patients with newly diagnosed upper aerodigestive tract cancers receiving treatment at Henry-Joyce Cancer Clinic.

OBJECTIVES:

Primary

  • To establish an estimate of the prevalence of baseline neurocognitive impairment prior to initiation of outpatient cancer treatment.
  • To establish an estimate of the incidence of neurocognitive impairment during outpatient cancer treatment.
  • To describe how neurocognitive functioning changes over time during cancer treatment.

Secondary

  • To identify sociodemographic and clinical factors associated with neurocognitive impairment.
  • To examine health-related outcomes associated with neurocognitive impairment.

OUTLINE: Patients undergo interview to complete measures of domain-specific neurocognitive functioning, global neurocognitive functioning, subjective neurocognitive functioning, delirium, physical functioning, symptom prevalence and distress, mood states, and medications at baseline before initiation of cancer treatment, at scheduled treatment visits, and at the follow-up visit 3 months after completion of cancer treatment.

Measures of comorbidity, alcohol use, sensory functioning (vision and hearing), and sociodemographic are completed at baseline only. Cancer-related information (diagnosis, staging, and sites of metastasis, if applicable), treatment-related information (planned treatment regimen - chemotherapy and/or radiation therapy), and current medications are obtained at baseline by medical record review.

Health service use and complications are assessed at each scheduled treatment visit and at the 3-month post-treatment follow-up visit. Measures of domain-specific neurocognitive functioning, coping, and quality of life are completed at baseline and at the 3-month follow-up visit.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients with newly diagnosed upper aerodigestive system cancers (head and neck, lung, and esophagus)
  • Neurocognitive Impairment
  • Delirium
  • Esophageal Cancer
  • Head and Neck Cancer
  • Lung Cancer
  • Other: Assessment of therapy complications
    Assessment of neurocognitive function, functional status, symptom prevalence and distress, and mood alterations
  • Other: Neurocognitive assessment
    Assessment of neurocognitive domains: attention/concentration, executive function, verbal learning, verbal memory, verbal fluency
  • Other: Quality-of-life assessment
    Assessment of quality of life using Cantrill's Ladder at baseline and 3 months post-treatment
Treatment
Patients undergoing treatment for head and neck, lung, and esophagus cancers
Interventions:
  • Other: Assessment of therapy complications
  • Other: Neurocognitive assessment
  • Other: Quality-of-life assessment
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
86
June 2013
May 2010   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Newly diagnosed solid tumors of the upper aerodigestive system, including cancers of the head and neck, esophagus, or lung
  • Receiving treatment at the Henry-Joyce Cancer Clinic at the Vanderbilt-Ingram Cancer Center
  • No known brain metastasis

PATIENT CHARACTERISTICS:

  • Able to hear, speak, and understand English
  • No prior diagnosis of other cancer except basal cell carcinoma

PRIOR CONCURRENT THERAPY:

  • No treatment plans including prophylactic cranial irradiation
Sexes Eligible for Study: All
21 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00533884
CDR0000565963
P30CA068485 ( US NIH Grant/Contract Award Number )
VU-VICC-SUPP-0751
No
Not Provided
Not Provided
Not Provided
Vanderbilt University Medical Center
Vanderbilt University Medical Center
National Cancer Institute (NCI)
Study Chair: Stewart M. Bond, PhD, RN Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP